BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32158919)

  • 1. Dynamic induction of drug resistance through a stress-responsive enhancer in acute myeloid leukemia.
    Williams MS; Somervaille TCP
    Mol Cell Oncol; 2020; 7(2):1705730. PubMed ID: 32158919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia.
    Williams MS; Amaral FM; Simeoni F; Somervaille TC
    J Clin Invest; 2020 Mar; 130(3):1217-1232. PubMed ID: 31770110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted nanopore sequencing for the identification of ABCB1 promoter translocations in cancer.
    Williams MS; Basma NJ; Amaral FMR; Williams G; Weightman JP; Breitwieser W; Nelson L; Taylor SS; Wiseman DH; Somervaille TCP
    BMC Cancer; 2020 Nov; 20(1):1075. PubMed ID: 33167906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia.
    Sucha S; Sorf A; Svoren M; Vagiannis D; Ahmed F; Visek B; Ceckova M
    Biomed Pharmacother; 2022 Jun; 150():112962. PubMed ID: 35462331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.
    Mathias TJ; Natarajan K; Shukla S; Doshi KA; Singh ZN; Ambudkar SV; Baer MR
    Invest New Drugs; 2015 Apr; 33(2):300-9. PubMed ID: 25597754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study.
    Boyer T; Gonzales F; Barthélémy A; Marceau-Renaut A; Peyrouze P; Guihard S; Lepelley P; Plesa A; Nibourel O; Delattre C; Wetterwald M; Pottier N; Plantier I; Botton S; Dombret H; Berthon C; Preudhomme C; Roumier C; Cheok M
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31500210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance: still a daunting challenge to the successful treatment of AML.
    Shaffer BC; Gillet JP; Patel C; Baer MR; Bates SE; Gottesman MM
    Drug Resist Updat; 2012; 15(1-2):62-9. PubMed ID: 22409994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
    Megías-Vericat JE; Martínez-Cuadrón D; Herrero MJ; Rodríguez-Veiga R; Solana-Altabella A; Boluda B; Ballesta-López O; Cano I; Acuña-Cruz E; Cervera J; Poveda JL; Sanz M; Aliño SF; Montesinos P
    Leuk Lymphoma; 2021 Mar; 62(3):659-668. PubMed ID: 33135528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WYE-354 restores Adriamycin sensitivity in multidrug-resistant acute myeloid leukemia cell lines.
    Ibrahim SM; Bakhashab S; Ilyas AM; Pushparaj PN; Karim S; Khan JA; Abuzenadah AM; Chaudhary AG; Al-Qahtani MH; Ahmed F
    Oncol Rep; 2019 Jun; 41(6):3179-3188. PubMed ID: 30942458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
    Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
    Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Butorphanol, a synthetic opioid, sensitizes ABCB1-mediated multidrug resistance via inhibition of the efflux function of ABCB1 in leukemia cells.
    Wen J; Zhang T; Shan ZM; Qi MY; Xiu HH; Liu L; Wu SZ; Jia Z; Xu KQ
    Oncol Rep; 2015 Aug; 34(2):755-62. PubMed ID: 26062728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients.
    Pravdic Z; Vukovic NS; Gasic V; Marjanovic I; Karan-Djurasevic T; Pavlovic S; Tosic N
    Radiol Oncol; 2023 Jun; 57(2):239-248. PubMed ID: 37078709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients.
    Scheiner MA; da Cunha Vasconcelos F; da Matta RR; Dal Bello Figueira R; Maia RC
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):959-69. PubMed ID: 22358301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mechanisms of drug resistance in leukemia.
    Ross DD
    Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy
    Wu X; Yin C; Ma J; Chai S; Zhang C; Yao S; Kadioglu O; Efferth T; Ye Y; To KK; Lin G
    Acta Pharm Sin B; 2021 Jul; 11(7):1885-1902. PubMed ID: 34386326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.
    Wang YJ; Kathawala RJ; Zhang YK; Patel A; Kumar P; Shukla S; Fung KL; Ambudkar SV; Talele TT; Chen ZS
    Biochem Pharmacol; 2014 Aug; 90(4):367-78. PubMed ID: 24937702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
    Corrêa S; Binato R; Du Rocher B; Ferreira G; Cappelletti P; Soares-Lima S; Pinto LF; Mencalha A; Abdelhay E
    Epigenetics; 2014 Aug; 9(8):1172-83. PubMed ID: 25089713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.